The future of the industry, redefined.
We are building the architecture for the next generation of pre-clinical pharmaceutical development. No compromises.
Why “Allotrope”
Same atoms. Different structure. Everything changes.
Carbon becomes pencil lead, diamond, or graphene depending on how its atoms are arranged. In a drug, that arrangement decides stability, solubility, and whether it works at all. Structure is everything, and we predict it.
>90%
of drugs fail in development
>10%
fail at this exact step
$1B+
bet on every single drug
Months
to years, per iteration
The Friction
The current pre-clinical landscape demands speed and precision. Each drug is a billion dollar bet, and minimizing that risk is key.
Speed allows for more iterations, more experiments, and ultimately better drugs. But the current process is a bottleneck that can take months to years. We need to break this barrier to unlock the next wave of medical breakthroughs.
The Legacy Trap
Existing solutions are precise but slow, or they require very significant upfront investment: supercomputers, or robotic wet labs.
We believe there is a better way, one that runs on standard hardware.
FIG. 01 — CRYSTAL UNIT CELL
Operating in Stealth
We are quietly engineering the solution: an AI-powered architecture for Crystal Structure Prediction at an unprecedented scale, speed, and precision. Several ML models are involved in this complex endeavor.
> Details strictly under NDA for select partners.
Built for the Vanguard
Academics
Streamlining the research that changes lives.
Pharmaceutical companies
Speeding up discovery of the best crystal structures.
Simulation software companies
Providing the vetted crystals for them to verify.
The people behind Allotrope
Two founders, one obsession: making structure prediction fast enough to matter.
